OTLK Outlook Therapeutics Inc

$OTLK we better be over $1 by Christmas or I’m gonna have to hear it from my entire family AGAIN 😑

$OTLK VERY BULLISH! LYTENAVA IS IN THE FINAL COUNTDOWN TO START SALES IN USA IN OHIO, MICHIGAN AND NORTH DAKOTA. AT ANY TIME SOON.

$OTLK Greetings to all the longs! It's been a while since last time I posted anything here. Holding 120K shares patiently. With the J-code and the first real sales numbers afterwards, the price share will be way above 1 and close to 2 dollars in Q3. My bet we'll see already a steady price above 1 in Q1. Also, after Q3 it will open the perfect window time for Big Pharma to buy us out. This has been my high tisk high reward satellite investment for more than 5 years now and I'm not selling... other than this I'm buying boring ETFs like crazy during this red market. Cheers!!!

$OTLK Just sitting tight and watching execution. Really like all the new additions to the team, and excited to see how the next few quarters look. This game is all about patience. Sit back and let time, management and the product do the work.

$OTLK My bet is no RS will be necessary. This will rocket nicely. RS is not good for them either with all of their own personal investments.

$OTLK shorts lended 2M shares today (200% of volume) and couldn't manage to get price down 🤣🤣 this is funny. They are no longer able to manipulate the stock. Commercialize ASAP and burn them! Please announce hot news monday pre-market to mess their entire week!

$OTLK Insider buys at more than 100% above the current share price just a few months ago. You don't make investments like that unless you believe in the company's story...

$OTLK I'm confident that the LYTENAVA launch is being meticulously planned and professionally executed. I expect a steady flow of positive commercial updates following the launch, progressively rebuilding market confidence and demonstrating real momentum. We could also see a strategic, non-dilutive financing agreement that would significantly strengthen investor confidence. A successful launch, consistent execution, and smarter financing could completely change market sentiment toward $OTLK. The next few months could be transformational. 🚀

$OTLK $IBRX $REGN At this point, considering all the milestones $OTLK achieved, this valuation is totally unrealistic in my view, with an FDA-approved product in a multi-billion-dollar market 👀

$OTLK No one should be surprised by this. This is the way it is going to be until they get this moving. The reasons for this are clear as a bell.

$OTLK There are no clear indications of an imminent reverse split. Most of the panic seems to be driven by bears spreading fear and making noise. The priority right now is launching LYTENAVA in the U.S. and unlocking its commercial potential. Launch first. Let the catalysts unfold. We'll see about the rest later. Ignore the noise. Focus on the fundamentals. 🚀

$OTLK What's important is they already have governance, policy and procedure in place. Lytenava orders have processed already. This isn't a BUILD, it's an EXPANSION. Dec 1 as a US launch should be doable.

$OTLK It is very plausible that in preparation for launch, the commercial team has already identified priority accounts, gauged interest levels, and is preparing those practices so that initial shipments can move quickly once the product is available. That kind of groundwork is standard and does not require public disclosure. 

$OTLK did the math, I’m pulling the trigger and buying another 20k shares on Monday, and as a result my new PT will adjust to $4

$OTLK Today, we're hoping to see $0.47, and we're getting closer and closer to the long-awaited LYTENAVA launch! Let's hope management has meticulously planned the commercial rollout, with a powerful series of positive announcements that could trigger the explosive, vertical rally we've all been waiting for — and frankly, deserve after so much patience. 💎 We firmly believe OTLK is massively undervalued. The market is pricing in a near-catastrophic scenario while completely overlooking the true potential and underlying value of LYTENAVA. The asset is worth FAR MORE than the current market capitalization suggests. 🔥 All we need now is strong execution, smart financing, and a steady flow of positive news to restore confidence. The market may be underestimating what's coming. 🚀📈 $OTLK #LYTENAVA #Undervalued #Bullish

$OTLK I believe this stock will trigger a good short squeeze when they launch based on what I see with the numbers.

$OTLK Plenty of room to run. Looks like a lot of activity starting up in December from the insurance companies. LFG!!

$OTLK I have to correct myself. KOD has just reclaimed the $100 level, making its market cap roughly 60 times that of OTLK at $0.43. Let that sink in. Apparently, hope alone is worth billions. 😉

$OTLK Is OTLK tracing the exact playbook of TARS? 📈🧪 The parallel between Tarsus (TARS) and Outlook Therapeutics (OTLK) is striking: both turned a compounded care standard into an FDA-approved blockbuster (Xdemvy vs Lytenava). The milestone alignment: 1️⃣ FDA Approval • TARS: ~$22–$24 (July '23) • OTLK: ~$0.45–$0.55 (Mid-'26) *Post-approval dilution occurred for both. 2️⃣ Commercial Launch • TARS: Fell to ~$17–$19 • OTLK: Stabilising at ~$0.45–$0.50 (Late '26) 3️⃣ Pre-J-Code Run • TARS: Rallied to ~$32–$36 (March '24) • OTLK: Permanent U.S. J-Code expected April '27 4️⃣ Post-J-Code Inflection (Q1-Q3) • TARS: Held $27.18 (Q1 post-code), then rocketed to $32.89 & $55.37 as sales hit $66M/qt. • OTLK: Late '27/28 will be the test. ⚠️ DISCLAIMER: They are not identical. OTLK may have more competition in its own space compared to TARS’, however 12 year exclusivity is a huge benefit. Apparently pre commercialization is the last low stock price phase in their life cycle. #Biotech #Stocks #OTLK #TARS

$OTLK It appears that the shorts are unable to take this lower from around 0.43, we may see a decent move up during next week as they start covering.